EGFR and lung adenocarcinoma: Another study completed by Ni et al. found that efatutazone and gefitinib synergistically inhibited the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway [72].